ALISO VIEJO, Calif., April 28, 2016 (GLOBE NEWSWIRE) -- Cianna Medical, Inc., today announced receipt of the 2016 Scientific Impact Award at the Society of Breast Surgeons (ASBrS) Annual Meeting for data presented validating the clinical utility of SAVI SCOUT® breast localization and surgical guidance system. The Scientific Impact Award is given to the clinical research presentation that is considered to have the greatest scientific impact on breast cancer care, as judged by surgeon attendees.
SCOUT®, an FDA-cleared breast lesion localization tool that uses micro-impulse radar to localize and direct the removal of non-palpable breast lesions, became available in late 2015. The technology has been rapidly adopted by physicians and is now in use at more than 50 medical centers across the U.S.
“According to a recent market report, the number of breast localization procedures is expected to nearly double by 2020,” noted Jill Anderson, President and CEO of Cianna. “We need advanced technologies like SCOUT that will help meet that growth by significantly reducing or eliminating the serious operational inefficiencies that exist with all current breast localization devices.”
Based on a separate research report, U.S.-based hospital executives have changed how they think about cost containment and are focusing their efforts on maximizing performance against quality metrics and driving operational efficiency.1 It has also been reported that nearly 40 percent of all healthcare providers are willing to shift toward technologically advanced options for breast lesion localization that do not require invasive wires or radiation and have been shown to improve patient care.2
“We have received favorable feedback from clinicians, patients and administrators indicating that SCOUT is helping to address unmet needs through improved workflow, simplified scheduling and high quality clinical results across diverse healthcare delivery settings,” said Terry Hardin, Director of Marketing and Technology, Cianna Medical.
The data presented during ASBrS showed that SCOUT achieved 100 percent surgical success, high clinical reproducibility and favorable physician and patient satisfaction. Additionally, 97 percent of patients in the study would recommend SCOUT to other women.3
The presentation on SCOUT was made by Nashville-based breast surgeon Pat Whitworth, M.D., on April 16. He accepted the award on behalf of Charles Cox, M.D., the Tampa, Fla.-based lead study investigator, himself and the other clinical study investigators. Dr. Whitworth is a breast surgical oncologist and Director of the Nashville Breast Center. Dr. Cox is Professor of Surgery and McCann Foundation Endowed Professor of Breast Surgery, University of South Florida College of Medicine, Director of The University of South Florida Breast Health Program and Medical Director of Morsani Ambulatory Surgery Center.
About SAVI SCOUT®
The FDA-cleared SCOUT system features micro-impulse radar to detect a reflector that is placed at the tumor site up to seven days before a lumpectomy or surgical biopsy. During the procedure, the surgeon scans the breast using the SCOUT handpiece, which emits infrared light and a micro-impulse signal to detect the location of the reflector. Real-time audible and visual indicators assist the surgeon in accurately locating the reflector, along with the target tissue. This higher level of localization precision allows the surgeon to plan a surgical approach that may result in a better cosmetic outcome.
About Breast Conservation Surgery
The goal in breast-conservation surgery is to remove all detectable cancer cells. Of the estimated 174,000 women who have breast conservation surgery each year, approximately 30 percent will require repeat surgery because cancer cells are not completely removed during the first procedure.
Developed more than 20 years ago, the standard preoperative technique for localizing non-palpable breast lesions is wire localization (WL). With this procedure, a wire is inserted into the breast by a radiologist to guide the surgeon to the target tissue. The most common challenges reported with current localization techniques include scheduling and workflow, surgical planning and guidance, high re-excision rates and a sub-optimal patient experience.
About Cianna Medical, Inc.
Cianna Medical develops, manufactures and markets innovative medical technologies that reduce costs, improve quality, and reduce the burden breast cancer treatment places on women and their families. Its SAVI® technologies are FDA-cleared and address unmet needs in the delivery of radiation therapy, tumor localization and surgical guidance.
For more information, call 866-920-9444 or visit www.ciannamedical.com
1 Available at: http://www.zsassociates.com/publications/articles/hospitals-have-spoken-how-medtech-can-benefit-from-the-affordable-care-acts-focus-on-outcomes.aspx. Accessed April 26, 2016
2 MarketandMarkets (2016). Breast Lesion Localization Methods Markets: Comparative Analysis and End User Preference Study.
3 Whitworth, P. (2016, April). A Prospective, SingleArm, Multi-Site, Clinical Evaluation of a Nonradioactive Surgical Guidance Technology for the Location of Nonpalpable Breast Lesions During Excision. Paper presented at the annual meeting of the American Society of Breast Surgeons, Dallas, TX.
Source:Cianna Medical Group